Log In
BCIQ
Print this Print this
 

Requip Once-Daily, Requip XL, ropinirole (Requip (extended-release))

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
Description24-hour extended-release formulation of a dopamine receptor agonist formulated using SKP's Geomatrix oral drug delivery technology
Molecular Target Dopamine D1 receptor
Mechanism of ActionDopamine D1 receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationParkinson's disease (PD)
Indication DetailsTreat Parkinson's disease (PD)
Regulatory Designation
PartnerGlaxoSmithKline plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$634.2M

$100.6M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/10/2016

$634.2M

$100.6M

0

Get a free BioCentury trial today